Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 Unmet Need: Treatment Tolerability 23
6.2.2 Unmet Need: Efficacy 23
6.2.3 Unmet Need: Disease Awareness 24
6.2.4 Unmet Need: Treatment Cost 25
6.2.5 Unmet Need: Shorter Treatment Duration 25
6.2.6 Unmet Need: Simplified Treatment Regimens 26
6.3 Unmet Needs Gap Analysis 26
6.4 Opportunities 27
6.4.1 Opportunity: Pan-genotypic HCV Regimen 27
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 27
6.4.3 Opportunity: Involvement of Immune System 28
7 Pipeline Assessment 29
7.1 Overview 29
7.2 Promising Drugs in Clinical Development 30
8 Daclatasvir, Asunaprevir, and Peginterferon Lambda 32
8.1 Overview 32
8.2 Efficacy 34
8.3 Safety 35
8.4 Dosing and Formulation 36
8.5 Potential Clinical Positioning 36
8.6 Potential Commercial Positioning 37
8.7 Pricing and Reimbursement 37
8.8 SWOT Analysis 38
8.9 Forecast 39
9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 44
9.3 Methodology 45
9.4 Forecasting Methodology 45
9.4.1 Percent Drug-Treated Patients 45
9.4.2 Patient Warehousing 46
9.4.3 General Pricing Assumptions 46
9.4.4 Generic Erosion 47
9.4.5 Pricing of Pipeline Agents 47
9.5 Physicians and Specialists Included in this Study 48
9.6 Survey of Prescribing Physicians 50
9.7 About the Authors 51
9.7.1 Author 51
9.7.2 Global Head of Healthcare 51
9.8 About GlobalData 52
9.9 Contact Us 52
9.10 Disclaimer 52